U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06839339) titled 'Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD' on Feb. 17.
Brief Summary: This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.
Study Start Date: Feb. 18
Study Type: INTERVENTIONAL
Condition:
Wet Age-related Ma...